Drug Trial Radar · NCT05042128
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
158
Actual
Start
Apr 13, 2022
Primary completion
Jun 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Australasian Gastro-Intestinal Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- University of Sydney
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the ASCEND clinical trial is to measure the effect of adding LSTA1 (certepetide), compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.
Conditions
- Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Cancer
Interventions
LSTA1Drug
LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Gemcitabine InjectionDrug
Chemotherapy drug provided as solution to be administered via IV infusion.
Nab paclitaxelDrug
Chemotherapy drug provided as solution to be administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From date of randomization to 18 months later, or death
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Border Medical Oncology
Albury, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Monash Medical Centre
Clayton, New South Wales, Australia
Lake Macquarie Private Hospital
Gateshead, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Calvary Mater Newcastle
Newcastle, New South Wales, Australia
Newcastle Private Hospital
Newcastle, New South Wales, Australia
Prince of Wales Hospital
Sydney, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia
ICON Cancer Centre, Gold Coast University Hospital
Southport, Queensland, Australia
Flinders Medical Centre
Adelaide, South Australia, Australia
Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Launceston General Hospital
Launceston, Tasmania, Australia
Northern Health
Epping, Victoria, Australia
Warringal Private Hospital
Heidelberg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Frankston Hospital
Melbourne, Victoria, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
St John of God
Subiaco, Western Australia, Australia
Dunedin Hospital
Dunedin, New Zealand
Waikato Hospital
Hamilton, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.